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Detection and mapping of haemoglobin variants
in blood fingermarks by MALDI MS for suspect
“profiling”†
Cameron Heaton,a Matthias Witt,b Laura Cole,a Jason Eyre,c Simon Tazzyman,c
Richard McColmd and Simona Francese *a
Over the past seven years Matrix Assisted Laser Desorption Ionisation Mass Spectrometry Profiling (MALDI
MSP) and Imaging (MALDI MSI) have proven to be feasible tools for the detection of blood and its prove-
nance in stains and fingermarks. However, whilst this capability as a confirmatory test addresses the
primary questions at the scene of a violent crime, additional intelligence recoverable from blood can also
prove important for investigations. A DNA profile is the most obvious and important example of such
intelligence; however, it is not always suitable for identification purposes, depending on quantity, age and
environmental conditions. Proteins are much more stable and determining the presence of haemoglobin
variants in blood recovered at a crime scene may provide associative and possibly corroborating evidence
on the presence of an individual at a particular location. This evidence gains more incriminatory value, the
lower the incidence of the variant in a certain geographical area or population and may contribute to nar-
rowing down the pool of suspects. In this study, a MALDI based mass spectrometric method has been
developed and tested on six haemoglobin variants for their fast and reliable identification and mapping in
blood fingermarks.
1. Introduction
Over the past seven years, Matrix Assisted Laser Desorption
Ionisation has proven its capability to detect and visualise
blood in stains and fingermarks.1–6 The compatibility with a
range of blood enhancement techniques as well as its feasi-
bility of application in aged blood (as old as 37 years5) confer
the technique operational significance. Recently, it has been
possible to provide additional information from this evidence
by establishing its human or animal provenance (down to
animal species) as well as discriminating this from other bio-
logical matrices4,6–9 and in a pre-validation study.6
Whilst reliable detection of blood and the additional infor-
mation on blood provenance address the first lines of a foren-
sic inquiry, other intelligence may also be useful and, in some
cases, crucial in informing investigations. A prime example of
vital intelligence is offered by DNA profiling, used to identify
the perpetrator or to establish foul play in a murder inquiry
without a body. However, DNA amplification, profiling and
matching may not always be possible depending on initial
DNA quantity, degradation, possible presence in a mixture and
the existence of a record in DNA databases. Although only of
an associative type, blood typing or detection of drugs or medi-
cations in a bloodstain or a blood fingermark may be impor-
tant to an investigation. Whilst a MALDI based method is
available for the former,10,11 there is no report in the literature
covering the latter.
Additional intelligence on the presence of Hb variants (Hb
var) could also be beneficial to narrow down the pool of sus-
pects, depending on their incidence and occurrence in certain
geographical areas or linked to the inhabiting multiethnic
population (although migration alters the geographical occur-
rence over time). In 2001 Weatherall and Clegg12 reported that
mutations in genes encoding for haemoglobin occurred in the
7% of the global population. However, in some parts of the
world, the sickle cell gene (HbS) can be present in up to 40%
of the population, and the HbE variant can be present in
excess of 60% of the population.12 Both instances suggest that
the detection of haemoglobin variants may be considered as
useful intelligence to narrow down the pool of suspects. A
genetic modification affecting the rate of synthesis gives raise
to haemoglobin conferring a thalassemic trait; a genetic modi-
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fication yielding a structural change in the form of amino
acidic substitutions in the protein chain, generates Hb var
which can also occur alongside ‘normal’ haemoglobin tetra-
mers within some individuals. Most Hb var are the result of a
single amino acid substitution on either the α or β chain,
although multiple substitutions can and do occur as well as
insertion or deletion of amino acids. When variants occur as
traits, an individual has one copy of an abnormal allele of the
mutated haemoglobin gene and one copy of the ‘normal’ hae-
moglobin gene (heterozygous), or two copies of the abnormal
allele (homozygous). For example, in the case of sickle cell hae-
moglobin, these are referred to as HbAS and HbSS respectively,
where someone with the trait may not display the severe symp-
toms of sickle cell disease. Haemoglobin A0 (HbA0 or “normal”
haemoglobin), is a tetramer containing two alpha subunits
and two beta subunits (α2β2) and accounts for 97–98% of the
total red blood cell Hb in a “normal” individual.13
According to the HbVar database (https://globin.bx.psu.
edu/globin/hbvar/), regularly updated and part of the Globin
Gene Server database [http://globin.cse.psu.edu/], there are a
total of 1833 known Hb var of which 1393 are haemoglobin
variants and 534 are thalassemias. Nine hundred and forty
one entries arise from a modification to the β gene. Swedan
et al. reported that more than 50 HbJ variants were known in
200814 but the Hb var database currently reports only 46 HbJ
variants, possibly indicating that the overall number of Hb
variants of 1831 may be a considerable under-estimation.
However, incidence is what makes their detection interesting
from a forensic perspective. Brunel et al. reported that in
their laboratory, only 30 variants are detected in over 12 000
tests per annum.15 In another example, as part of the North
American “biometric screening programme” for the reduction
and management of the healthcare costs and health risks of
their employees, the Houston Methodist Hospital tested
13 913 individuals in 2.5 months.16 Of this number, only
3.77% exhibited an Hb variant for a total of 11 different var-
iants. Amongst these 524 employees, the HbS trait was
present in 2.85% of the individuals, the HbSS disease in
0.03%, the HbC trait in 0.61%, the HbCC disease in 0.01%
and the HbE trait in 0.13% of the individuals. Due to the
potential contribution in forensics, this study has selected
and investigated the six most common and clinically signifi-
cant Hb variants, namely HbS, HbJ-Baltimore, HbC, HbE,
HbD-Iran and HbD-Punjab/Los Angeles, all bearing modifi-
cations to the β globin chain. Prevalence in the UK varies by
region due to the ethnic component of the distribution
dependant on migration. As a reference, Sheffield, where the
authors operate, has performed 10 196 Haemoglobinopathy
screens last year, of which 464 (4.6%) presented a variant.
According to Public Health England, Sheffield is considered
high prevalence (>2.0% screen positive), although this per-
centage may be skewed upwards by the fact that Sheffield is a
referral lab for many surrounding areas and beyond (Jason
Eyre, personal communication).
Of these variants, HbS gives raise to the most important of
the haemoglobinopathies (sickle cell anemia), where types C,
E and D Punjab/Los Angeles might lead to sickle cell anemia
when associated with HbS.17,18
Sickle cell anemia is a life-threatening haemoglobinopathy
characterised by low solubility of Hb which determines the
rod-like shape of the red cells (sickle).19,20 The low solubility of
this variant arises from a substitution of valine for glutamic
acid at the 6th amino acid position in the beta globin gene (β6
Glu → Val). In 2008 Swedan et al. observed that in the US, the
sickle trait has a prevalence of 8–10% among African
Americans, and it is calculated that ∼1/500 African Americans
and 1/1000 Hispanics have sickle cell anemia.14 HbJ-Baltimore
was first reported in 1963 by Baglioni and Weatherall in a
black American family21 and it arises from a substitution of
glycine for an aspartic acid at the 16th amino acid position
(β16 Gly → Asp). HbC and HbE are also frequently observed in
some populations; the former has a high occurrence in Africa,
while the latter is common in South East Asia.18,22 The HbC
variant is caused by the substitution of a glutamic acid for a
lysine at the 6th position in the beta globin gene (β6 Glu →
Lys), whereas HbE arises from a substitution of a glutamic
acid for a lysine at the 26th amino acid position in the beta
globin gene (β26 Glu → Lys). HbD Los Angeles was the 4th Hb
var to be discovered and was described by Itano in 1951.23 It
arises from a substitution of a glutamic acid for a glutamine at
the 121st position in the β globin chain (β121 Glu → Gln). In
1962 Baglioni discovered that other HbD variants that had
emerged had the same molecular composition as HbD-Los
Angeles, one of these being HbD-Punjab.24 Since then, this
variant is denominated HbD-Punjab/Los Angeles. Whilst it is
reported as one of the most common Hb var worldwide after
HbS and HbC,25 its prevalence varies according to geographi-
cal location; in the Northwest India (the Punjab region) it has
a prevalence of 2%, dropping to 1% in Western India. This
variant has also been detected in some European countries
such as Italy, Belgium and Austria as well as Turkey.26–29 For
Italy, the findings cannot exclude either an independent origin
or a spread from India due to migration.26 For Belgium the
latter is instead considered unlikely,27 whereas for Austria a
spread from Turkey is considered possible.28 Whilst these var-
iants are described as common in these four countries,25 it
does not mean that they have a high incidence. For example in
the Belgium study, in 1986 it was reported that over the course
of 9 years, 19 000 individuals had been screened for haemo-
globin abnormalities and only nine unrelated carriers of
HbD-Punjab/Los Angeles were discovered;26 in Turkey, it
occurs in 0.2% of the population.25 Dass et al.30 reported
HbD-Iran as a rare variant which was first discovered in a
family in central Iran in 1973.31 This variant arises from a sub-
stitution of a glutamic acid for a glutamine at the 22nd amino
acid position in the β globin chain (β22 Glu → Lys). Table 1
summarises the modifications on the β globin chain for each
of the variants of interest.
In healthcare, there are a number of techniques that are
currently used to screen for Hb variants including cation
exchange HPLC, tandem mass spectrometry, acid and alkaline
gel electrophoresis (or isoelectric focusing electrophoresis),
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capillary zone electrophoresis and molecular methods,
depending on the target of the screening,32,33 with HPLC
being the more commonly used technique across the UK.
Depending on the laboratories, a combination of the
methods above is used to detect as many variants as possible.
However, to the authors’ knowledge no forensic screening for
Hb variants has ever been reported in the literature so far. The
techniques are not only generally time consuming but are also
not applicable to blood fingermarks as they require destruc-
tion of the evidence (due to swabbing and extraction). In the
work presented here, MALDI MSP and MSI have been investi-
gated to evaluate the possibility to detect the six selected hae-
moglobin variants in blood and to visualise them in blood fin-
germarks. The use of diverse mass spectrometry instrumenta-
tion has shown that, whilst the highest sensitivity is required
to detect (and map) the Hb var under investigation, MALDI
MS is, within the system investigated, a suitable technique to
recover this type of intelligence from blood. With further
optimisation it could also be a valid alternative/addition to the
current clinical diagnostics methods for Hb var screening.
2. Experimental
2.1 Materials
Trifluoroacetic acid (TFA), α-cyano-4-hydroxycinnamic acid
(α-CHCA) phosphorous red and TLC sheets were purchased
from Sigma Aldrich (Poole, UK). Acetonitrile, (ACN) was pur-
chased from Fisher Scientific (Loughborough, UK).
Lyophilised sequencing grade modified Trypsin was obtained
from Promega in 20 μg vials (Southampton, UK). RapiGest was
obtained in 1 mg vials from Waters (Waters Corp, Manchester,
UK). Double sided conductive tape was purchased from TAAB
(Aldemastor, UK), Intellislides (glass slides) were made avail-
able by Bruker Daltonik (GmbH, Bremen, Germany). Indium
tin oxide (ITO) slides were purchased from Sigma Aldrich
(Poole, UK). Six Haemoglobin variants were investigated by
MALDI MS, MS/MS and MSI namely, HbC, HbD-Iran,
HbD-Punjab/Los Angeles, HbE, HbJ Baltimore and HbS. HbA0
(“normal” Hb) was also included as a reference. Samples were
available as standards (HbA0, and HbS were purchased from
Sigma Aldrich (Dorset, UK) and a mixed Hb AFSC standard
was purchased from Sebia (Lisses, France), as they were not
commercially available individually, or as patients’ blood.
Patients’ blood was provided by Sheffield Teaching Hospitals
under the IRAS and the Sheffield Hallam University Ethics
approvals 160418 and ER6558932 respectively. These samples
were analysed using three types of MALDI Mass Spectrometers.
2.2 Instruments and instrumental conditions
Three sets of data were acquired from three MALDI mass spec-
trometers, namely the MALDI QToF Synapt G2 HDMS (Waters
Corp. Manchester, UK), MALDI TOF/TOF rapifleX and MALDI
qTOF timsTOF fleX (ttfleX, Bruker Daltonik GmbH, Bremen,
Germany).
Data acquisition: MALDI MSP. The Synapt G2 HDMS is sup-
plied with a neodymium-doped yttrium aluminium garnet
(Nd:YAG) laser which was set at a repetition rate of 1 kHz. Data
acquisition was performed over the m/z range 600–2500 in
positive mode. A 0.5 μL spot of saturated red phosphorus solu-
tion in ACN was used as the internal calibrant for each sample
by acquiring a spectrum in the same acquisition instance as
the sample. MALDI MS/MS spectra were obtained setting the
resolution of the quadrupole at 4.4 and 11 for low mass (LM)
and high mass (HM) respectively. Argon was used as the col-
lision gas; with the cooling gas set at 10.0 a.u. and the trap gas
at 7.5 a.u. The trap collision energy was ramped between 80
and 100 eV. The MALDI rapifleX is equipped with a Nd:YAG
355 nm SmartBeamTM 3D laser operating at a repetition rate
of 10 kHz. The instrument was calibrated using a Bruker
peptide calibration standard mono mix between m/z
1046–2455. MS spectra were obtained in reflectron positive
mode in the mass range m/z 600–3200, with laser power of 35
a.u. The MALDI ttfleX mass spectrometer is equipped with a
Smartbeam 3D laser operated at a repetition rate of 10 kHz.
When using the ttfleX for MALDI MSP, the instrument was
calibrated in positive mode over the m/z range 100–3000 using
red phosphorus. In MS mode, five hundred laser shots per
spectrum were fired and typically 10 acquired single spectra
were summed. MS/MS spectra were obtained by ramping the
collision energy between 80–130 eV. Five thousand laser shot
per single spectra were acquired and typically 10 single spectra
were summed.
Data acquisition: MALDI MSI. Imaging data were acquired
on the MALDI Synapt G2 HDMS and on a MALDI ttfleX mass
spectrometer.
In the former case, side by side blood stain images were
acquired in the mass range m/z 600–2000, setting the laser
power at 250 a.u. When using the MALDI ttfleX mass spectro-
meter, blood fingermarks (including overlapping) were
acquired at a lateral resolution of 50 µm, a laser power of 65%
and accumulating 600 laser shots per pixel. The instrument
was previously calibrated in ESI mode using Agilent low con-
centration calibration mix (G1969-85000) and operated in posi-
tive mode and in full scan over the m/z range 100–3000.
Data processing. In silico determination of the proteotypic
peptide sequences (across the six variants and the HbA0) was
Table 1 Hb variants investigated in this study, nature and location of the amino acid mutation
Variant HbA0 HbC HbD-Punjab/Los Angeles HbD-Iran HbE HbJ-Baltimore HbS
Chain α2β2 α2βC2 α2βD2 α2βD2 α2βE2 α2βJ2 α2βS2
Amino acid modification NA Glu > Lys Glu > Gln Glu > Gln Glu > Lys Gly > Asp Glu > Val
Modification position NA 6 β chain 121 β chain 22 β chain 26 β chain 16 β chain 6 β chain
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performed by preliminarily identifying the amino acid
mutation in the β-globin chain using a database of haemo-
globin variants accessible at https://globin.bx.psu.edu/globin/
Hbvar/. Subsequently, an in silico digestion with trypsin was
performed using Uniprot KB (https://www.uniprot.org/). Here
the β haemoglobin chain sequence was in silico digested
setting the maximum number of missed cleavages to 2 and to
yield MH+ monoisotopic peptides up to m/z 3000. The results
were navigated by identifying the peptides with up to 3 clea-
vages sites containing the amino acid modification for each
variant. Finally proteotypic peptides were identified through
filtering out peptides with the same theoretical m/z and those
differing by less than 15 ppm (Table 2).
MALDI MS and MS/MS spectra acquired from all three
MALDI Mass Spectrometers were exported to txt files and pro-
cessed using mMass, an open source mass spectrometry
tool.34,35 For the Synapt G2 HDMS and rapifleX data, spectra
were batch processed by smoothing using the Savitzky–Golay
algorithm, a m/z window size of 0.2 and 1 smoothing cycle;
peak picking was also performed by setting the S/N threshold
at 4.0, the absolute and relative intensity threshold at 0.0 a.u.
and 0.5 respectively and the picking height at 100. MALDI MS
and MS/MS spectra acquired using the ttfleX instrument were
preliminarily processed using DataAnalysis software (Bruker
Daltonik GmbH, Bremen, Germany) and then converted into
txt file to be further processed in mMass where no further
smoothing was applied; the peak picking was performed for
all ttfleX spectra by setting the S/N threshold at 20.0, the absol-
ute and relative intensity threshold at 0.0 a.u. and 0.5 respect-
ively and the picking height at 98 a.u. Haemoglobn variant
proteotypic peptides were used to build a database in mMass
for the automatic assignment of Hb var in MS mode.
Depending on the instrument employed and calibration
achieved, a different mass tolerance for assignment was
employed: ±13 ppm for Synapt, ±11 pm for rapifleX and
±4 ppm for ttfleX MS spectra.
ttfleX MALDI MS images were generated using SCiLSlab
2021a software (Bruker Daltonik, Bremen, Germany) with a
mass accuracy of ±15 ppm, using no de-noising (to avoid loss
of ridge detail) and normalising against RMS. Brightness and
contrast were adjusted to optimal values to improve clarity of
ridge detail. Synapt MALDI MS images were generated using
the HDI software (Waters Corp Manchester) and normalised
against the total ion current.
2.3 Trypsin digestion
For MALDI MS Profiling experiments, all in-solution trypsin
digestions were performed as follows: 5 µL of blood sample
were dissolved in 1 mL of H2O. Ten µL of diluted blood
sample was added to 40 µL 40 mM AmBic. Nine µL of trypsin
at 20 µg mL−1 (containing 0.1% RapiGest) was added and the
mixture was incubated at 37 °C for 1 h. Two µL 5% TFA were
then added to stop the proteolysis.
For MALDI MSI analysis on the Synapt G2 HDMS instru-
ment, 9 layers of trypsin gold at 100 µg mL−1 (containing 0.1%
RapiGest) were sprayed over the blood stains using a
SunCollect matrix sprayer (SunChrom, Germany), at a flow rate
of 2 µL min−1. The stains were incubated in a sealed container
containing 50 : 50 MeOH : H2O at 37 °C for 3 h. The samples
were then sprayed with 5 layers of α-CHCA matrix at 5 mg
mL−1 in 70 : 30 ACN:0.5% TFA at 4 µL min−1.
Blood contaminated fingermarks were prepared by deposit-
ing 10 µL of patient blood samples (containing either one of
the Hb variants investigated) on the fingertip of a in house 3D
printed silicon fingertip and quickly dragging the blood
around with the pipette tip until covering the mark. The fin-
gertip was subsequently pressed on an Intellislide to generate
a Hb var contaminated blood fingerprint. An additional
sample was prepared by pressing a silicon fingertip contami-
nated with HbC blood and a silicon fingertip contaminated by
HbJ-Baltimore blood on an Intellislide to generate overlapping
marks. These marks were subsequently enhanced using Acid
Table 2 Expected proteotypic peptides for the six haemoglobin variants selected in this study used to build the mMass database for automatic
peptide assignment. The bold font indicates the amino acid mutation
βHb variant and proteotypic peptide Proteotypic peptide sequence Expected m/z
HbC (2–18) VHLTPKEKSAVTALWGK 1865.0646
HbC (2–9) VHLTPKEK 951.5626
HbC (2–7) VHLTPK 694.4251
HbS (2–9) VHLTPVEK 922.5361
HbS(2–18) VHLTPVEKSAVTALWGK 1836.0381
HbE (19–41) VNVDEVGGKALGRLLVVYPW TQR 2569.4253
HbE (10–31) SAVTALWGKVNVDEVGGKAL GR 2227.2197
HbE (10–27) SAVTALWGKVNVDEVGGK 1829.9760
HbE (19–31) VNVDEVGGKALGR 1313.7175
HbE (19–27) VNVDEVGGK 916.4739
HbD-Punjab/Los Angeles (122–145) QFTPPVQAAYQKVVAGVANA LAHK 2508.3726
HbD-Punjab/Los Angeles (122–147) QFTPPVQAAYQKVVAGVANA LAHKYH 2826.5051
HbD-Punjab/Los Angeles (122–133) QFTPPVQAAYQK 1377.7164
HbD-Iran (19–41) VNVDQVGGEALGRLLVVYPW TQR 2569.3889
HbD-Iran (10–31) SAVTALWGKVNVDQVGGEAL GR 2227.1831
HbD-Iran (19–31) VNVDQVGGEALGR 1313.6812
HbJ-Baltimore (10–31) SAVTALWDKVNVDEVGGEAL GR 2286.1726
HbJ-Baltimore (1–18) MVHLTPEEKSAVTALWDK 2055.0583
HbJ-Baltimore (10–18) SAVTALWDK 990.5259
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Black 1, a commonly used crime lab technique for blood
enhancement in fingermarks, according to the methanol-
based protocol described by the Home Office edited finger-
mark visualisation manual.36 Sequencing grade Trypsin was
reconstituted in 20 mM of ammonium bicarbonate to a final
concentration of 25 ng µL−1. Trypsin was deposited using the
HTX M3 sprayer (HTX Technologies LLC, US) at a temperature
of 30 °C and a pressure of 10 psi. The flow rate and the nozzle
height were set at 30 µL min−1 and 40 mm respectively. A total
of 8 layers of trypsin were deposited at a velocity of 750 mm
min−1 and using a criss-cross pattern with 2 mm track
spacing. Following trypsin deposition, the glass slides contain-
ing the fingermarks were placed on top a two glass tubes or
15 mL Sarstedt tubes in a lunch box. Ten µL of water were
pipetted on top of the glass slide but far away from the finger-
prints. The lunch box contained 40 mL of a saturated K2SO4
solution (75 g in 500 mL water) and a further spoonful of
K2SO4 was added before sealing the lunch box. The slides were
incubated for 2 h at 50 °C. Overlapping fingermarks were sub-
mitted to MALDI MSI on a ttfleX mass spectrometer.
2.4 Matrix deposition
For MALDI MS and MS/MS data acquisition on the Synapt G2
HDMS, α-cyano 4 hydroxycinnamic acid (α-CHCA) was pre-
pared at a concentration of 5 mg mL−1 in 70 : 30 ACN:0.5%
TFA, and 0.5 µL was pipette mixed with the sample on a
MALDI target plate.
For MALDI MS on the rapifleX, α-CHCA was prepared at
5 mg mL−1 in 70 : 30 ACN:0.5% TFA and 0.5 µL was spotted on
top of the sample spots that had been allowed to dry in a
vacuum desiccator. For MALDI MS and MS/MS on the ttfleX
mass spectrometer, haemoglobin standard and patient blood
digests were mixed 1 : 1 with α-CHCA solution saturated in 30/
70 ACN/0.1%TFA. One µL of this solution was applied on an
Anchor 800 target plate. After drying (crystallization) the
MALDI spot was washed once with 3 µL water containing 0.1%
TFA as a clean-up procedure.
For MALDI MSI on the Synapt, 5 layers of α-CHCA at
5 mg mL−1 in 70 : 30 ACN:0.5% TFA were sprayed at 2 µL
min−1.
For MALDI MSI on the ttfleX, a solution of 10 mg mL−1 of
α-CHCA, in 70 : 30 ACN : TFAaq 0.2%, was sprayed using a HTX
M3 sprayer (HTX Technologies LLC, US) at 75 °C, 10 psi
pressure and at a flow rate of 120 µL min−1. The nozzle height
was set at 40 mm. Four layers of matrix were sprayed with
2 mm track spacing and a velocity of 1200 mm min−1.
3. Results and discussion
In this study, the first of its kind, a combined proteomics-
MALDI MSP/MSI based approach was developed to quickly
identify (in bloodstains) and map (in blood fingermarks) six
most common haemoglobin variants (Hb var), HbS, HbC,
HbD-Punjab/Los Angeles, HbD-Iran, HbE and HbJ-Baltimore.
Hb var screening belongs to clinical diagnostic settings.
However, it has been pursued here through a forensic perspec-
tive as a means to provide additional intelligence from examin-
ation of blood evidence. A relatively large sample set of
patients’ blood, containing different Hb var was used for
method development and investigated on the MALDI Synapt
G2 system, for a total of 44 samples which were spotted and
analysed in triplicate. The samples were received in different
batches at different times over the course of 2 years in which
instrumental conditions may have varied. Although here the
44 samples are discussed as a whole, dates of shipment have
been highlighted. The identity of the samples was blind to the
analyst processing the data until the Hb var assignment was
completed. Table S1† reports a summary of the putative detec-
tion of the Hb variants during method development on the
Synapt G2 HDMS instrument.
The HbD-Punjab/Los Angeles variant was detected only in
one out of the seven supplied patients’ samples and the
HbJ-Baltimore variant was detected in the only patient’s
sample supplied of this kind. The three normal haemoglobin
samples (HbA0) and the two HbD-Iran samples were always
correctly labelled as “no variant detection” and HbD-Iran
respectively.
Nine out of ten patients’ samples were correctly labelled
with the HbS variant reflecting the high ionisability of the pro-
teotypic peptide 2–9. The next best result was achieved for the
HbC variant which was correctly identified in 8/11 patients’
samples. Finally, of the ten HbE patients’ samples, six samples
were correctly labelled as HbE. It is important to note that as
quantification is not performed, it is not possible to establish
whether the variant detected indicates that a patient is hetero-
zygous or homozygous for the variant identified. For example,
in the case of sickle cell anaemia heterozygous HbS, the
variant is indicated as HbAS whereas the pathology as HbSS.
Our results would report HbS, regardless of whether the
patients have a trait (HbAS) or the actual pathology (HbSS).
Table S2† reports the accurate list of proteotypic peptides
m/z assignments (using the custom built mMass library shown
in Fig. 2) relating to 1 replicate per samples only, for
readability.
An additional batch of nine patients’ blood samples was
received and submitted to the MALDI Synapt (3 replicates per
sample) as well as to additional two state of the art MALDI
mass Spectrometers, namely rapifleX (3 replicates per sample)
and timsTOF fleX (ttfleX) (2 replicates per sample) to ascertain
whether correct putative identification frequency could be
improved as well as confirming identity using tandem MS.
Although it is difficult to directly compare on paper the sensi-
tivities of the three MALDI instruments based on the manufac-
turer specifications, these are all very sensitive instruments;
the sensitivity specifications are all based on the measurement
of the same peak at m/z 1570.7 relating to [Glu1]-
Fibrinopeptide B (GluFib) as follows: (i) Synapt: 10 fmol
GluFib at S/N > 90 : 1; (ii) rapifleX: 250 amol GluFib at S/N ≥
200 : 1 shown on Bruker AnchorChip™ target with 2000 laser
shots; (iii) ttfleX: S/N > 100 : 1 for 250 amol GluFib on target
S/N with 2000 laser shots. MALDI MS analyses were conducted
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once again in a blind fashion and using the custom built
mMass database of proteotypic peptides (Table 2). Isopro soft-
ware, based on the Yergey algorithm,37 was used to calculate
the molecular formula of each peptide, given the amino acidic
sequence, to build the mMass library. Table 3 reports the Hb
var identification for each patient sample on the three instru-
ments (only one replicate per instrument is shown). As it can
be seen from Table 3, in terms of correct identifications, the
ttfleX performed better than the rapifleX and the Synapt with
8/9 correct identifications and mass accuracies ranging
between −3.2 and 3.1 ppm, versus 6/9 and 7/9 correct identifi-
cations using the rapifleX and the Synapt respectively; taking
into account one replicate per sample with the highest mass
accuracy of Hb var identifying signals, mass accuracies on the
rapifleX and Synapt ranged between −3.7 and 10.5 ppm and
−8.6 and 12.1 ppm respectively. The Synapt performed better
than the rapifleX in terms of number of correct putative IDs.
Sample 846 was correctly identified as HbE both on the ttfleX
and the Synapt, whereas the rapifleX incorrectly indicated the
presence of HbD-Iran. Sample 848 was correctly identified as
HbD-Punjab on the ttfleX, whereas the other two instruments
were unable to detect any variant. However, when sample 849,
containing again the HbD-Punjab variant, was analysed,
neither of the mass spectrometers were able to detect it and a
result of “no Hb variant” was yielded; all the assignments are
reported in Table 3.
The two variants were quantified in patients 848 and 849 at
41.3% and 41.6%, therefore there was no appreciable differ-
ence that can explain lack of detection of this variant in
patient 849. However, when preliminary Synapt experiments
were performed, HbD-Punjab was the least successfully
detected variant with only 1/7 samples correctly identified and
5/7 samples showing no HbD-Punjab/Los Angeles related
signals (Table S1†).
It is possible that the HbD-Punjab/Los Angeles proteotypic
peptides are generated below the limits of detection due to a
combination of proteolytic concentration and ionisation
efficiency.
In situ MALDI MS/MS analyses are generally and notoriously
challenging for non-single analyte samples; this is why
shotgun proteomics of complex samples (such as blood) is
more frequently conducted by LC MS/MS, where the separation
dimension improves on the selection of the precursor ion.
Given the observed performances, in situ MALDI MS/MS ana-
lyses were nevertheless attempted in a comparison between
the Bruker Daltonik higher end instrument, the ttfleX, and the
Waters Synapt G2. The ttfleX enabled confirmation via MS/MS
of all the variants except for HbE in patient 845 as the precur-
sor ion could not be isolated and for patient 849, yielding no
variants signals. For the reminder of the samples, fragment
ions were assigned in high mass accuracy, ranging between −5
and 4.9 ppm (across samples and ion fragments) (Table S3†).
Table 3 MALDI MS of patients’ blood samples containing different variants. The same set of samples was analysed on three different instruments,
namely the timsTOF fleX (ttfleX), the rapifleX and the Synapt G2 HDMS. Cells are coloured in green if the correct variant was identified; cells are
coloured in red if the incorrect Hb var or no Hb var was identified. Spectra were run in duplicates on the ttfleX and in triplicates on the rapifleX and
on the Synapt. In the table only one replicate m/z per proteotypic peptide detected is reported having the lowest relative error
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The Synapt G2 yielded reliable confirmatory MS/MS spectra for
samples 843, 850 and 851 with a mass accuracy ranging
between −18.5 and 7.8 ppm (across samples and ion frag-
ments) (Table S3†).
As an example, Fig. 1 shows a comparison of MS and MS/
MS spectra obtained on the ttfleX and on the Synapt for
patient sample 843, with this being the sample for which the
Synapt MS/MS analyses yielded the highest number of ion frag-
ments. Both in MS mode (Fig. 1A and B) and in MS/MS mode
(Fig. 1 Ai, Bi), the ttfleX exhibited superior sensitivity.
In MS mode, the HbJ-Baltimore proteotypic peptide
labelled with a star was detected as more than twice as intense
on the ttfleX; in MS/MS mode, 14 ion fragments could be
assigned using ttfleX versus 13 on the Synapt, with 11 ion frag-
ments in common. Although this difference is not meaningful
in terms of performance, the ion fragments in common were
generally detected with higher intensity on the ttfleX. A final
observation is noteworthy in that the ttfleX detected the
peptide at nominal m/z 2227 for two different samples (846
and 851) and was able to easily discriminate HbE (10–31)
(sample 846) from HbD Iran (10–31) (sample 851) at a theore-
tical m/z of 2227.2197 and 2227.1831 respectively. Table S3†
reports all of the ion fragments identified within the MS/MS
spectra acquired on the ttfleX and on the Synapt.
In silico methods were employed to establish both protein
and species specificity. In other words, it was assessed
Fig. 1 MALDI MS and MS/MS analysis of sample 843 on ttfleX (A, Ai) and Synapt (B, Bi); Ai and Bi show the MALDI MS/MS spectra of the ion at
nominal m/z 2286 (HbJ-Baltimore (10–31) SAVTALWDKVNVDEVGGEALGR) leading to the confirmation of the HbJ-Baltimore variant. The ttfleX
instrument exhibited a superior sensitivity both in MS mode (A, B – star symbols indicate the proteotypic peptide (HbJ-Baltimore (10–31)) and in MS/
MS mode (Ai, Bi – star symbol indicates the fragments detected in common).
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whether or not the proteotypic peptides employed to detect
each of the Hb var: (1) could only derive from those human β
Haemoglobin variants and (2) are specific to human. For this
purpose, the amino acid sequences of all proteotypic peptides
were screened against the UniProtKB/Swiss-Prot protein knowl-
edgebase release 2021_01 containing 564 277 manually anno-
tated and reviewed proteins from 14 014 species. Using the
peptide search tool against the entirety of the taxonomy
included in the database, searches were run only against the
manually annotated and reviewed proteins. Table S4† reports
the summary of these searches.
In brief, using the “peptide search” tool, only 8/19 proteoty-
pic peptide sequences yielded a hit and all hits were against
human haemoglobin except for HbC (2–7) peptide. This
sequence was matched to proteins in Fungi, metazoa, bacteria
and human; interestingly, this sequence in human matches to
the thyroid adenoma-associated protein. This protein is
expressed in pancreas, adrenal medulla, thyroid, adrenal
cortex, testis, thymus, small intestine and stomach and as
such it seems unlikely to be detected in blood. However, to dis-
sipate any doubt on the identity of the detected peptide, the
additional detection of the HbC (2–9) could be checked to
confirm the presence of HbC. The Blast tool was also used in
parallel to check homologies and HbC (2–7) yielded no hits
having a 100% homology. This was the case also for all the
proteotypic peptides except for HbE (10–27) and HbJ-Baltimore
(10–31). In the former case, a 100% homology with β haemo-
globin was found for both human and primates and in the
latter case a 100% homology with β haemoglobin was found
for the species Gorilla gorilla.
Whilst detection of Hb var in blood stains and/or blood fin-
germarks may contribute to narrowing down the pool of sus-
pects, visualisation of these variants onto the fingermark ridge
pattern provides important and direct associative evidence. A
first MALDI MS imaging experiment was performed aiming at
the visualisation of Hb var and differentiation in the presence
of blood of different origin. Initially, two bloodstains from
HbS and normal HbA0 patients’ blood were deposited side by
side and imaged on a MALDI Synapt G2 as a proof of concept.
Fig. 2 shows the visualisation of the aspecific α-Hb peptide at
m/z 1529.68 which was present in both stains as expected.
In contrast, the HbS proteotypic peptide at m/z 922.48 was
only visible in the HbS bloodstain and well discriminated from
the stain containing the normal HbA0 variant, as both the
MALDI images and the spectra extracted from the regions of
interest of patients 1 and 2 show (Fig. 2B). A subsequent
attempt to image overlapping HbS/HbA0 fingermarks failed on
this mass spectrometer. For this reason, blood fingermarks
were produced using patient blood samples containing the six
variants under investigation and imaged using the ttfleX
MALDI system. MALDI MSI data reflected at large the data
obtained through MALDI MSP using the same instrument;
generally, Hb var proteotypic peptides that were detected in
MS mode and confirmed by MS/MS, were also mapped onto
the ridge pattern of the mark and contributed to some degree
of ridge detail and minutiae visualisation. In particular Fig. 3
reports the distribution maps of the proteotypic peptides HbC
(2–7) at m/z 694.420 (i), HbC (2–9) at m/z 951.563 (ii), HbE
(10–27) at m/z 1829.976 (iii), HbE (10–31) at m/z 2227.220 (iv),
HbD-Punjab/Los Angeles (121–133) at m/z 1377.719 (v),
HbD-Iran (19–31) at m/z 1313.687 (vi), HbD-Iran (10–31) at m/z
2227.183 (vii), HbJ-Baltimore (10–31) at m/z 2286.173 (viii) and
HbS (2–9) at m/z 922.536 (ix), within a mass accuracy of
±10 ppm.
The HbS variant proteotypic peptide provided the most
ridge flow and minutiae visualisation, in line with the better
ionisation efficiency amongst all other Hb variant proteotypic
peptides observed in MALDI MS mode. Other Hb var proteoty-
pic peptides were visualised on the fingerprint samples
(largely in a “dotted” fashion) but they are not reported in
Fig. 2 MALDI MS imaging of two bloodstains from HbS and HbA0 patients (patients 1 and 2 respectively) on the Synapt G2 HDMS system. Panel A
shows visualisation of the aspecific α-Hb peptide at m/z 1529.680 in both stains as expected. Panel B shows the presence of the HbS proteotypic
peptide at m/z 922.48 only in the bloodstain of the HbS patient as also confirmed in the ROIs extracted spectra.
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Fig. 3 MALDI MS images of Hb var proteotypic peptides from silicon fingertips contaminated with patients’ blood. (a) Optical image of the blood
mark; (b) MALDI MS images of haem at m/z 616.178; (c) MALDI MS images of α-haemoglobin peptides at nominal m/z 1530; ((i)–(ix)) MALDI MS
images of proteotypic Hb var peptides detected and confirmed in MALDI MS and MS/MS mode. Proteotypic peptides are shown for HbC (2–7) at
m/z 694.420 (i), HbC (2–9) at m/z 951.563 (ii), HbE (10–27) at m/z 1829.976 (iii), HbE (10–31) at m/z 2227.220 (iv), HbD-Punjab/Los Angeles (121–
133) at m/z 1377.719 (v), HbD-Iran (19–31) at m/z 1313.687 (vi), HbD-Iran (10–31) at m/z 2227.183 (vii), HbJ-Baltimore (10–31) at m/z 2286.173 (viii)
and HbS (2–9) at m/z 922.536 (ix), within a mass accuracy of ±10 ppm.
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Fig. 3 as they were undetected in Profiling mode. It is interest-
ing to note that the highest quality/quantity of ridge detail
deriving from Hb var proteotypic peptides, was provided by
HbS and HbD-Punjab/Los Angeles blood generated finger-
prints. These prints correspond to the optical images showing
the faintest presence of blood. In other instances, where
optical images clearly and strongly showed the presence of
blood, the corresponding MALDI images of Hb var peptides
were fainter and exhibited a poorer ridge coverage.
Indeed, there is an optimal trypsin/substrate ratio and evi-
dently in the poorer quality MS images, the substrate (Hb) is
in excess and falling out of the optimal ratio with the enzyme,
as opposed to the ratio for HbS and HbD-Punjab/Los Angeles.
The Hb-Baltimore MS image does not follow this trend;
although the corresponding optical image also shows a very
weak presence of blood, the MALDI MS image also generates
poor quality and clarity of ridge detail. However, this instance
can be explained by the generally lower ionisation efficiency of
the HbJ-Baltimore proteotypic peptide, as also observed in the
profiling analyses; an additional hypothesis is that the amount
of HbJ-Baltimore sits outside the optimal trypsin/substrate
ratio where trypsin is, in this instance, present in excess
(leading to more auto-proteolysis events).
Fig. 3 also reports for each Hb var image, the corresponding
haem at nominal m/z 616 and the aspecific αHb peptide at
nominal m/z 1530. These additional images show that, in terms
of fingerprint images, the haem group performs better than Hb
deriving peptides yielding the most complete and continuous
ridge pattern with the most minutiae. In practice, this occurrence
suggests that when examining a blood mark by MALDI MSI, the
ridge pattern should be preferably reconstructed by visualising
haem whereas the presence of the variants could be visualised
and superimposed on the haem mass image to provide
additional intelligence on the suspect. Interestingly, the
HbD-Punjab Los Angeles (121–133) peptide localised with a
higher intensity in the left bottom corner area, exactly where the
signals of haem and α-Hb peptide at m/z 616.178 and 1529.737
respectively are almost absent. It is speculated that this proteoty-
pic peptide experiences ion suppression exerted by haem and
the α-Hb peptide and, therefore, ionises better in those areas
where these signals are much less intense or absent.
It is also important to note that, although better than the
Hb peptides, the quality of the haem image reflects that of a
non-ideal fingermark ridge pattern (“non-textbook”), with
smudged areas and interrupted ridge flow. This instance ulti-
mately reflects (i) the imperfections of the fingertip surface of
3D printed silicon finger, (ii) the inhomogeneity of the coating
of the silicon fingertip with blood and (iii) the difficulty of con-
trolling the pressure and angle when using this artefact to
generate blood fingerprints. Notwithstanding the challenges,
silicon fingertips have to be employed instead of human fin-
gertips due to blood being a biohazard. However, in real crime
scenes, blood fingermarks are also less than ideal, with blood
pooling and partial or discontinuous ridge detail due to the
careless and unintentional deposition. Altogether, the imaging
data presented here demonstrate the ability to map the six Hb
variants investigated.
A subsequent experiment was conducted in which two
blood fingerprints were overlapped during deposition; in par-
ticular one fingerprint was generated using patient blood con-
taining the HbC variant and the other by using patient blood
containing the HbJ-Baltimore variant (Fig. 4).
These overlapping prints were pre-enhanced using a blood
enhancement technique, namely Acid Black 1, to simulate
operational conditions.
A preliminary observation to make is that overlapping
blood marks at real crime scenes may be deposited in several
ways. In this instance, the blood in the first print was still wet
when the second wet blood fingerprint was overlapped. This
occurrence would have generated a certain degree of ridge
Fig. 4 MALDI MS images of overlapping fingerprints contaminated with blood containing HbC and HbJ-Baltimore variants respectively and pre-
enhanced with acid black 1. HbJ-Baltimore blood fingerprint (m/z 2286.173) has been separated from HbC blood fingerprint (m/z 694.426) as the
overlay of the two ion signals demonstrates; a fourth ion has been imaged at m/z 768.310 showing clearly two ulnar loops (labelled with the black
arrows in the zoom in inset), indicating the presence of two fingermarks.
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smudging and analyte migration. Additionally, the marks were
generated using 3D printed silicon fingertips to mitigate the
biohazard, which have not allowed generation of clear ridge
detail, due to the lack of sebaceous material that helps ‘fix’ the
blood marks on surfaces and the inflexibility of the moulds
compared to real fingertips. As a result, these overlapping fin-
gerprints were not “textbook models” either. The MALDI
Imaging data reflected the quality of the mark deposition and it
was not possible to obtain good quality ridge detail. In terms of
the separation of the fingerprints, although it was not possible
to obtain two distinct ridge patterns, Fig. 4 very clearly shows
that it is possible to indicate the presence of two prints and two
donors, compatibly with the prior application of a typical crime
lab blood enhancement technique, through to the detection
and visualisation of the two proteotypic peptides HbJ-Baltimore
at m/z 2286.173 (Fig. 4b) and HbC (Fig. 4c) at m/z 694.426. The
image of an unidentified ion at m/z 768.310 shows additional
ridge flow but most importantly corroborates the presence of
2 marks due to the visualisation of two ulnar loops indicated by
the black arrows in the zoomed inset.
This initial work, limited to the six most common Hb var-
iants, demonstrates in principle the possibility to inform inves-
tigation on the presence of any of these variants in blood evi-
dence. This intelligence could be important associative evidence
to narrow down the pool of suspects. An interesting prospect of
this research involves the hypothesis to attempt ethnic and/or
geographic provenance. The former hypothesis is formulated on
the knowledge that, for example, sickle cell anaemia is prevalent
in the African American and Hispanic populations.12 The
second hypothesis has stemmed from the observation reported
by one of the co-authors routinely screening Hb variants in the
Sheffield laboratory serving many surrounding areas and
beyond. The detection of HbD-Punjab is often an indication of
the possible provenance of the donor of the geographical
location; Sheffield/Rotherham area has a large South Asian
population (predominantly of Pakistani heritage where the HbD
Punjab variant is present in approx. 0.8% of the population)
therefore the detection of this variant often rightly indicates a
geographical location of the donor in the Sheffield/Rotherham
(Jason Eyre, personal communication). However, a thorough
study statistically investigating the correlation between Hb var
prevalence and ethnicity/geographic provenance is needed to
prove both hypotheses. Furthermore it is also important to
factor in demographics when assessing the prevalence of var-
iants as large populations from a certain ethnic background
may go unscreened (for example University students from
abroad), and a better indication of prevalence may be gained
from looking at the incidence in the country of ethnic origin.
The use of a combined proteomic/MALDI approach is also
interesting as a possible alternative or as a preliminary screen-
ing in clinical settings to reduce analytical time. In fact,
although CE-HPLC or CE allow to easily discriminate for
example HbD-Punjab/Los Angeles from HbS or Hb O-Arab
from HbE and HbC,15 these methods are still time consuming,
whereas the MALDI screening is faster and can easily discrimi-
nate between HbD Punjab/Los Angeles and HbS and HbC
from HbE as shown in this study. However, further investi-
gation and improvements are needed to demonstrate
both robustness and quantitative capabilities; studies are
needed to assess the possibility to distinguish between traits
and pathology (for example between HbAS and HbSS) as well
as the association of other variants with HbS leading to pathol-
ogy (meaning the detection of both variants in the blood
sample).
4. Conclusions
In this work, detection and mapping of haemoglobin variants
(Hb var) in bloodstains and blood fingermarks have been con-
ducted through a combined proteomics-MALDI based
approach. Different MALDI instrumentation with different sen-
sitivity specifications has been employed, highlighting the
need for high end equipment to reliably detect all of the six
Hb var investigated (HbS, HbC HbD-Punjab/Los Angeles,
HbD-Iran, HbE, HbJ-Baltimore). The opportunity to detect and
map Hb var could provide associative evidence to narrow down
the pool of suspects during an investigation. An examination
of the relevant literature has shown that there are many screen-
ing programmes across the world at birth and/or in workplaces
including detection of Hb var. Whilst these programmes are
aimed at prevention at reducing healthcare costs, the Hb var
medical records could in principle be accessed during an
investigation of a person of interest and compared with the Hb
var findings at a crime scene. Additional research is required
to investigate detectability of additional variants, compatibly
with blood enhancement techniques, as well as robustness of
the method against different environmental conditions and
evidence age. Additional work is also required to fully under-
stand the potential for Hb var to provide a meaningful indi-
cation of ethnicity as well as geographical provenance based
on data on their prevalence. Finally, this work highlights the
potential to provide an alternative or first screening method
for Hb var that could be used in clinical settings. However,
this hypothesis also needs further research.
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